Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Department of Laboratory Animal Science, Fudan University, Shanghai, China.
Immunology. 2019 Jul;157(3):248-256. doi: 10.1111/imm.13065. Epub 2019 May 29.
Down-regulated chemerin expression has been reported to correlate with poor prognosis of several types of cancer including melanoma. All-trans retinoic acid (atRA) is a potent inducer of chemerin, and we previously reported that atRA inhibited murine melanoma growth through enhancement of anti-tumor T-cell immunity. Here, we aimed to investigate whether loss of endogenous chemerin accelerated melanoma growth and whether chemerin was involved in the melanoma-inhibitory effect of atRA. We demonstrated that chemerin was constitutively expressed in the skin, which was down-regulated during murine melanoma growth. Rarres2 mice, which are deficient in chemerin, exhibited aggravated tumor growth and impaired tumor-infiltrating natural killer (NK) cells that express CMKLR1, the functional receptor of chemerin. Topical treatment with atRA up-regulated skin chemerin expression, which was primarily derived from dermal cells. Moreover, atRA treatment significantly enhanced tumor-infiltrating NK cells, which was completely abrogated in Rarres2 mice and Cmklr1 mice, suggesting a dependency of NK cell recruitment on the chemerin-CMKLR1 axis in melanoma. Despite comparable melanoma growth detected in wild-type mice and Cmklr1 mice, lack of CMKLR1 partially abrogated the melanoma-inhibitory effect of atRA. This may be due to the inability to enhance tumor-infiltrating NK cells in Cmklr1 mice following atRA treatment. Collectively, our study suggests that down-regulation of chemerin could be a strategy used by cancers such as melanoma to impair anti-tumor NK cell immunity and identifies a new anti-tumor mechanism of atRA by up-regulating chemerin to enhance CMKLR1-dependent NK cell recruitment.
下调趋化素表达与多种癌症(包括黑色素瘤)的不良预后相关。全反式维甲酸(atRA)是趋化素的有效诱导剂,我们之前报道过 atRA 通过增强抗肿瘤 T 细胞免疫来抑制鼠黑色素瘤的生长。在这里,我们旨在研究内源性趋化素的缺失是否会加速黑色素瘤的生长,以及趋化素是否参与了 atRA 对黑色素瘤的抑制作用。我们证明趋化素在皮肤中持续表达,而在鼠黑色素瘤生长过程中下调。缺乏趋化素的 Rarres2 小鼠表现出肿瘤生长加剧和浸润肿瘤的自然杀伤(NK)细胞受损,这些 NK 细胞表达趋化素的功能性受体 CMKLR1。atRA 的局部治疗上调了皮肤趋化素的表达,主要来自真皮细胞。此外,atRA 治疗显著增强了肿瘤浸润 NK 细胞,而在 Rarres2 小鼠和 Cmklr1 小鼠中完全被阻断,这表明 NK 细胞募集依赖于黑色素瘤中的趋化素-CMKLR1 轴。尽管在野生型小鼠和 Cmklr1 小鼠中检测到可比的黑色素瘤生长,但缺乏 CMKLR1 部分阻断了 atRA 的黑色素瘤抑制作用。这可能是由于在 atRA 治疗后 Cmklr1 小鼠中无法增强肿瘤浸润性 NK 细胞。总之,我们的研究表明,黑色素瘤等癌症下调趋化素可能是一种策略,以损害抗肿瘤 NK 细胞免疫,并确定了 atRA 通过上调趋化素增强 CMKLR1 依赖性 NK 细胞募集来增强抗肿瘤机制的新机制。